StackTerminal.Health

BETA

Research-only: Calm + Focus (Selank + Semax)

B84· Mostly solid
Public 06 Feb 2026

Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.

Research-only: Calm + Focus (Selank + Semax)
Selank
Daily
MODERATE
1mg
Semax
Daily
LOW
10mg
No interactions detected
Each dose includes evidence rationale · doses personalized to your weight
Stack note
Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

Sign in to keep a private note on Research-only: Calm + Focus (Selank + Semax).
AI risk assessment
Context: No wearable data
PROAI risk assessment is available with Pro.
See plans
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
2
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
Selank
Take ~15 min before the intended effect window
Reaches peak plasma concentration in ~15 min. Half-life ~0.5h.
Semax
Take ~15 min before the intended effect window
Reaches peak plasma concentration in ~15 min. Half-life ~0.5h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements
2 items
Daily • Lyophilized
Claims of anxiolysis come from limited clinical literature; quality varies.
1mg
Anxiety symptom measures
Low
Population: Patients with generalized anxiety disorder/neurasthenia (reported clinical study)
Study type: Clinical-biological study (older literature)
Dose context:

Clinical literature reports anxiolytic effects in patient cohorts, but study designs & reporting standards vary & limit certainty.

Citation: Zozulia et al., (2008) — Efficacy and possible mechanisms of Selank in GAD and neurastheniahttps://pubmed.ncbi.nlm.nih.gov/18454096/
Anxiolytic effect vs. phenazepam in anxiety disorders
Low
Population: 60 patients with phobic-anxiety and somatoform disorders
Study type: Comparative clinical study
Dose context:

Selank showed pronounced anxiolytic & mild nootropic effects compared with phenazepam; the anxiolytic effect persisted for approximately one week after the last dose. Methodology reflects older Russian clinical reporting standards, limiting generalizability.

Citation: Kolik et al. (2014) — Comparison of the anxiolytic effect and tolerability of selank and phenazepam in anxiety disordershttps://pubmed.ncbi.nlm.nih.gov/25176261/
Daily • Lyophilized
Added manually
10mg
Mechanistic cognitive pathway modulation
Low
Population: Preclinical / mechanistic work
Study type: Mechanistic study
Dose context:

Mechanistic literature suggests Semax may influence hippocampal BDNF/trkB-related signaling; this is supportive biology rather than definitive clinical efficacy.

Citation: Dolotov et al., (2006) — Semax analog with cognitive effects (mechanistic)https://pubmed.ncbi.nlm.nih.gov/16996037/
Overall brain health evidence appraisal
Low
Population: Humans (evidence review)
Study type: Independent evidence review
Dose context:

An independent cognitive vitality report reviews Semax & emphasizes limited high-quality human clinical evidence for cognitive outcomes.

Citation: Alzheimer's Drug Discovery Foundation (ADDF) — Semax Cognitive Vitality Reporthttps://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf
Neurotrophin signaling & gene expression after cerebral ischemia (mechanistic)
Low
Population: Rats (ischemia/reperfusion model)
Study type: Mechanistic/animal
Dose context:

Animal work demonstrates that Semax activates transcription of neurotrophins (BDNF, TrkC, TrkA) & suppresses pro-inflammatory gene expression after cerebral ischemia; this is not direct proof of cognitive improvement in healthy humans.

Citation: Shadrina et al., (2010) — Semax and Pro-Gly-Pro activate neurotrophins after cerebral ischemia (rat model)https://pmc.ncbi.nlm.nih.gov/articles/PMC11498467/

Similar community stacks

Avoid reinventing the wheel: fork a community stack that matches your category tags, then edit it.

Browse all community stacks →
gutdigestionresearch-only

Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).

KPV
1mg
BPC-157
1mg
Magnesium (Glycinate)
400mg
New
View
recoveryskinresearch-only

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
GHK-Cu
1mg
New
View
recoveryjointsresearch-only

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
New
View